Stem cell specialists for healthcare – discover what the future holds for those companies Who are the top stem cell developers and producers? And what are their sales outlooks? Visiongain’s new report shows you their potentials from 2015. In this study, you will discover the therapies, results, trends in R&D, opportunities and revenue forecasts.
You will find data and analysis on cellular technologies transforming human medicine. Our study analyses 23 leading companies in the US, Europe, Israel and Asia-Pacific. You will hear how stem cell producers can progress and gain, discovering their potentials.
Please read on to examine those organisations and find what revenue the fast-growing and potentially large market could generate in future. See what’s possible with stem cell technology.
Forecasts and other data to benefit your authority on those biotechnologies and applications In our new study you will find profiles of 23 prominent stem cell companies and analyses of their industry. You can discover sales results, R&D advances and revenue forecasting. Explore, from 2015, those firms’ capabilities, portfolios and commercial prospects.
You will also gain 55 tables, 29 charts and six interviews with the industry. Discover the views of authorities from ReNeuron, Apceth, Pluristem, Gamida Cell, and others, regarding stem cell technologies.
See how you can benefit your research, analyses and decisions, also saving you time and helping your influence and authority. The following sections explain the prospects for that biotechnology.
United States (US) – leading organisations and their potentials First our study provides discussions, analyses and commercial outlooks for 10 US-based stem cell firms:
You can read what the future holds for those cellular biology companies, including research trends and some revenue predictions to 2025.
Our study then analyses Asian organisations, explaining that region’s potential.
Stem cell specialists based in the Asia-Pacific region – what developments are possible? You can also discover the commercial outlooks for six top researchers, developers and producers of stem cells in Asia:
Our analyses show the possibilities for advancing technology and raising business performance, assessing where the commercial prospects exist. Also you will see revenue forecasting to 2025.
The report then analyses Europe and Israel, showing those countries’ activities and potentials.
Companies based in Europe and Israel – what successes can they achieve? Our analysis also shows you the progress and prospects for seven European and Israeli companies:
Our work shows where sales growth can occur. Many opportunities remain in the industry, with high, expanding revenues possible in the next decade. You can also explore the clinical testing and plans for launching products.
Our study also assesses the world industry, showing you its potential revenues from 2015 to 2025.
Predictions for the worldwide stem cells market – see the industry’s sales potential Our report also forecasts revenues to 2025 for the overall world stem cells industry and five submarkets:
• Central nervous system (CNS) uses • Cardiovascular (CV) applications • Cancer treatment (oncology) • Other therapy using those biological agents • Non-therapeutic cellular products using the technologies.
You will find overall revenues reaching $13.8bn in 2019, with high growth to 2025. Discover what the future holds for those technological advances and their providers.
You can also examine the forces driving and restraining the industry – social, technological, economic and political forces. And you can assess strengths, weaknesses, opportunities and threats.
Technologies and issues shaping that industry and market – explore progress and potential Our study explains those stem cell technologies and other forces influencing the market. There you can explore the developments and forces, including these.
• Regulations for that cellular research and technology, and its applications • Embryonic stem cells – potentials in tissue repair and regenerative medicine • Autologous and allogeneic agents, including T cell therapy • Novel treatments for cancer and other applications, e.g. diabetes and bone growth, including progress of clinical trials and product launches.
And also these influences, among others:
• Umbilical cord blood – applications and approvals for that tissue and cell banking • Regional distribution of the stem cell industry’s 2014 revenues • Non-therapeutic pharma applications – screening and toxicity studies in drug development.
You will also examine full transcripts of exclusive interviews with companies, finding information to help you stay ahead on commercial progress, outlooks and future trends. This will help you in your industry understanding. Avoid missing out.
Ways Pharma Leader Series: Top Stem Cell Technology Companies 2015-2025 helps In particular, our new investigation gives you this knowledge to benefit your work:
• Profiles of 23 leading stem cell companies in North America, Europe, Israel and Asia – assess the products, R&D, progress, results, strategies and alliances • Revenues to 2025 for that overall market at world level and for five submarkets – discover the potential sales, seeing those technologies’ commercial prospects • Competition, demands and opportunities – explore what affects the stem cells industry, finding what influences participants’ sales and determines their futures • Interviews with developers, producers and marketers – find what participants in that field think, say and do, helping you stay ahead with industry knowledge.
Information found nowhere else, benefiting your research, analyses and decisions Our report provides independent data. You will receive competitive intelligence found only in our work, seeing where progress and the prospects are. You can examine the commercial possibilities.
With our original analysis you’re less likely to fall behind in information or miss crucial opportunities. See how you could save time and effort. So benefit your plans, decisions and influence, helping you gain competitive advantage.
And by trying our new analysis on stem cells you can explore the trends, R&D and sales predictions. Avoid missing out – please order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1. Report Overview
1.1 Top Stem Cell Technology Companies: Overview
1.2 Global Stem Cell Technology Market Segmentation
1.3 Why You Should Read This Report
1.4 How this Report Delivers
1.5 Main Questions Answered by this Report
1.6 Who is this Report For?
1.7 Methods of Research and Analysis
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain
1.11 Glossary
2. The Global Stem Cell Technology and Applications Market 2015-2025
2.1 The Stem Cell Technologies and Applications Market in 2014
2.2 Non-therapeutic Applications Constitutes the Largest Segment in 2014, Oncology the Largest Therapeutic Area
2.3 Global Stem Cell Technology and Applications Market: Regional Breakdown, 2014
2.4 Global Stem Cell Technology and Applications Market Forecast 2015-2025
2.5 Fast Growth Owing to Therapeutic Potential, Drug Screening and Emerging Markets
2.6 Global Stem Cell Technology and Applications Market Forecast by Therapeutic Segment 2015-2025
2.7 Therapeutic Applications to Overtake Non-Therapeutic Applications in 2020
2.8 How Will Market Shares for the Different Segments Within the Stem Cells Market Change from 2014-2025?
2.9 Drivers and Restraints for the Stem Cell Technology and Applications Market, 2015-2025
3. Leading US Stem Cell Technology Companies
3.1 Regulation, Patentability and ‘Homologous Use’ in the US
3.1.1 Embryonic Stem Cell Research Remains Controversial in the US
3.2 Osiris Therapeutics
3.2.1 Developed and then Sold the Rights to Osteocel and Prochymal
3.2.2 Grafix Reports Impressive Clinical Trial Results, Now Available in More Sizes
3.2.2.1 Is Grafix Really a ‘Stem Cell Product’?
3.2.3 OvationOS: Stem Cell Product for Regeneration of Bone Tissue
3.2.4 Cartiform - Launched to Address a Potential $500m Market
3.2.4.1 Partnership with Arthrex for the Commercialisation and Development of Cartiform
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
The global single cell analysis market was valued at US$3,255.0 million in 2022 and is projected to grow at a CAGR of 15.1% during the forecast period 2022-2032.
The number of people who are blind or have poor vision is expected to rise considerably in the coming years. The growing elderly population is one of the key drivers of the Ophthalmic Devices Market’s upward trend.
The growing global health system has made significant contributions to protecting and promoting human health. However, long-standing, developing, and reemerging infectious disease risks continue to plague the planet
The major driving factor contributing towards the growth of pharmaceutical contract manufacturing market are increase in investments in pharmaceutical R&D, rise in number of patent expiry, rising demand of generic drugs, and investment in advanced manufacturing technologies. However, use of serialization can thwart the market growth.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
